DecisionDx-UM is a prognostic test that accurately determines the metastatic risk associated with ocular melanoma tumors of the eye. Ocular melanoma is a term commonly used to describe tumors of the uveal tract such as uveal melanoma, choroidal melanoma, ciliary body melanoma, and iris melanoma. The DecisionDx-UM test was clinically validated on these tumors of the uveal tract. DecisionDx-UM assesses the gene expression profile (GEP) of a subset of genes which are differentially expressed in primary tumor cells compared to cells that have undergone transformation to a metastatic phenotype.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| CSTL | CASTLE BIOSCIENCES INC | 2026-04-02 15:46:07 | 25 | 0.16 | 0.64 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CSTL | 0001447362 | CASTLE BIOSCIENCES INC | US14843C1053 | 2549007M2Q4HLR1XD252 | 770701774 | Nasdaq | 8071 | Services-Medical Laboratories | 1231 | DE | 1500 W. PARKWOOD AVE. | FRIENDSWOOD | TX | 77546 | UNITED STATES | US | 866-788-9007 | 1500 W. PARKWOOD AVE., FRIENDSWOOD, TX, 77546 | 1500 W. PARKWOOD AVE., FRIENDSWOOD, TX, 77546 | — | — | — | — | — | — | 576,000,000 | 29,686,314 | 29,731,198 | DecisionDx-UM is a prognostic test that accurately determines the metastatic risk associated with ocular melanoma tumors of the eye. Ocular melanoma is a term commonly used to describe tumors of the uveal tract such as uveal melanoma, choroidal melanoma, ciliary body melanoma, and iris melanoma. The DecisionDx-UM test was clinically validated on these tumors of the uveal tract. DecisionDx-UM assesses the gene expression profile (GEP) of a subset of genes which are differentially expressed in primary tumor cells compared to cells that have undergone transformation to a metastatic phenotype. | 2026-04-02 17:37:19 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 576,000,000 | -11,000,000 | -1.8739 | 29,731,198 | 1,217,089 | 4.2684 |
| 2024 | 587,000,000 | 276,000,000 | 88.746 | 28,514,109 | 1,064,126 | 3.8766 |
| 2023 | 311,000,000 | -161,000,000 | -34.1102 | 27,449,983 | 874,367 | 3.2901 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Kristen M. Oelschlager | Chief Operating Officer | 2024 | 506,415 | 13,926 | 1,563,738 | 342,701 | 20,150 | 2,446,931 |
| Tobin W. Juvenal | Chief Commercial Officer | 2024 | 506,415 | 13,926 | 1,563,738 | 342,701 | 20,150 | 2,446,931 |
| Derek J. Maetzold | CEO, President | 2024 | 715,572 | 0 | 5,283,595 | 921,657 | 20,250 | 6,941,074 |
| Kristen M. Oelschlager | Chief Operating Officer | 2023 | 482,300 | 9,646 | 0 | 312,530 | 24,008 | 828,484 |
| Frank Stokes | Chief Financial Officer | 2023 | 488,800 | 4,888 | 0 | 316,742 | 69,820 | 880,250 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 883 |
| 2024 | 761 |
| 2023 | 610 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 344,229,000 | 332,069,000 | 219,788,000 |
| Cost Of Revenue | 71,028,000 | 60,205,000 | 44,982,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 51,850,000 | 52,041,000 | 53,618,000 |
| General And Administrative Expenses | 229,323,000 | 200,047,000 | 180,152,000 |
| Operating Expenses | 387,039,000 | 323,399,000 | 287,765,000 |
| Operating Income | -42,810,000 | 8,670,000 | -67,977,000 |
| Net Income | -24,158,000 | 18,245,000 | -57,466,000 |
| Earnings Per Share Basic | -0.83 | 0.66 | -2.14 |
| Earnings Per Share Diluted | -0.83 | 0.62 | -2.14 |
| Weighted Average Shares Outstanding Basic | 28,986,000 | 27,776,000 | 26,802,000 |
| Weighted Average Shares Outstanding Diluted | 28,986,000 | 29,255,000 | 26,802,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 116,729,000 | 119,709,000 | 98,841,000 |
| Marketable Securities Current | 182,776,000 | 173,421,000 | 144,258,000 |
| Accounts Receivable | 43,382,000 | 51,218,000 | 38,302,000 |
| Inventories | 10,254,000 | 8,135,000 | 7,942,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 361,097,000 | 360,154,000 | 295,635,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | — | — | — |
| Other Assets Non Current | 3,769,000 | 1,228,000 | 1,440,000 |
| Total Assets Non Current | 217,459,000 | 171,081,000 | 157,705,000 |
| Total Assets | 578,556,000 | 531,235,000 | 453,340,000 |
| Accounts Payable | 18,711,000 | 6,901,000 | 10,268,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 417,000 | 278,000 | — |
| Other Liabilities Current | — | 1,076,000 | — |
| Total Liabilities Current | 68,677,000 | 49,392,000 | 47,667,000 |
| Long Term Debt | 10,057,000 | 10,023,000 | — |
| Other Liabilities Non Current | — | — | 25,000 |
| Total Liabilities Non Current | 39,006,000 | 26,008,000 | 14,404,000 |
| Total Liabilities | 107,683,000 | 75,400,000 | 62,071,000 |
| Common Stock | 30,000 | 28,000 | 27,000 |
| Retained Earnings | -224,284,000 | -200,126,000 | -218,371,000 |
| Accumulated Other Comprehensive Income | 267,000 | 230,000 | 136,000 |
| Total Shareholders Equity | 470,873,000 | 455,835,000 | 391,269,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 40,771,000 | 15,997,000 | 12,330,000 |
| Share Based Compensation Expense | 45,893,000 | 50,320,000 | 51,219,000 |
| Other Non Cash Income Expense | -153,000 | -268,000 | -635,000 |
| Change In Accounts Receivable | -6,876,000 | 12,643,000 | 14,930,000 |
| Change In Inventories | 2,142,000 | 193,000 | 3,962,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | 366,000 | -262,000 | 330,000 |
| Change In Accounts Payable | 3,078,000 | -4,372,000 | 5,707,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 64,347,000 | 64,866,000 | -5,626,000 |
| Purchases Of Marketable Securities | 188,714,000 | 205,729,000 | 189,075,000 |
| Sales Of Marketable Securities | 189,200,000 | 183,900,000 | 186,500,000 |
| Acquisition Of Property Plant And Equipment | 36,021,000 | 28,326,000 | 13,621,000 |
| Acquisition Of Business | — | 0 | 0 |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -60,367,000 | -50,137,000 | -16,183,000 |
| Tax Withholding For Share Based Compensation | 11,657,000 | 8,762,000 | 5,134,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 2,416,000 | 2,981,000 | 2,709,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | 0 | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -6,960,000 | 6,139,000 | -2,298,000 |
| Change In Cash | -2,980,000 | 20,868,000 | -24,107,000 |
| Cash At End Of Period | 116,729,000 | 119,709,000 | 98,841,000 |
| Income Taxes Paid | 1,601,000 | 2,503,000 | 198,000 |
| Interest Paid | 59,000 | 434,000 | 11,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -0.83 | 0.66 | -2.14 |
| Price To Earnings Ratio | -46.8675 | 40.3788 | -10.0841 |
| Earnings Growth Rate | -225.7576 | -130.8411 | -17.0543 |
| Price Earnings To Growth Ratio | 0.2076 | -0.3086 | 0.5913 |
| Book Value Per Share | 16.2448 | 16.4111 | 14.5985 |
| Price To Book Ratio | 2.3946 | 1.6239 | 1.4782 |
| Ebitda | 19,021,000 | 37,445,000 | -44,927,000 |
| Enterprise Value | 1,021,300,400 | 630,822,400 | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0.0222 | 0.0226 | — |
| Capital Expenditures | — | — | — |
| Free Cash Flow | — | — | — |
| Return On Equity | -0.0513 | 0.04 | -0.1469 |
| One Year Beta | 0.6187 | 1.3785 | 1.6854 |
| Three Year Beta | 1.0409 | 1.7852 | 1.9136 |
| Five Year Beta | 1.5211 | 1.1784 | 1.132 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Cotton Rodney | Director | 2026-03-26 | 5,329 | A | 19,331 |
| Cotton Rodney | Director | 2026-03-26 | 5,329 | D | 5,330 |
| MAETZOLD DEREK J | Director, Pres. & Chief Exec. Officer | 2026-03-26 | 550 | A | 22,029 |
| MAETZOLD DEREK J | Director, Pres. & Chief Exec. Officer | 2026-03-26 | 550 | D | 21,479 |
| MAETZOLD DEREK J | Director, Pres. & Chief Exec. Officer | 2026-03-26 | 1,357 | D | 50,209 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Josh Gottheimer | 2022-04-17 | NJ05 | Sale (Partial) | 2022-03-15 | Joint | $1,001 - $15,000 |
| Josh Gottheimer | 2021-01-07 | NJ05 | Purchase | 2020-12-21 | Joint | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | 2025-12-31 | 11,173,441 | 287,235 | 38.9 |
| HSBC HOLDINGS PLC | 2025-12-31 | 760,344 | 19,486 | 39.02 |
| Rockefeller Capital Management L.P. | 2025-12-31 | 3,384 | 87 | 38.8966 |
| Caitong International Asset Management Co., Ltd | 2025-12-31 | 81,651 | 2,099 | 38.9 |
| Sunbelt Securities, Inc. | 2025-12-31 | 39 | 1 | 39 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Global X Funds | 2026-01-31 | Global X Russell 2000 ETF | RSSL | 12,890 | 507,737.1 | 0.0367 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2026-01-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 40,015 | 1,576,190.85 | 0.0589 |
| GOLDMAN SACHS TRUST | 2026-01-31 | Class P Shares | GSXPX | 43,197 | 1,701,529.83 | 0.1832 |
| GOLDMAN SACHS TRUST | 2026-01-31 | Class R6 Shares | GTTUX | 43,197 | 1,701,529.83 | 0.1832 |
| GOLDMAN SACHS TRUST | 2026-01-31 | Investor Shares | GTTTX | 43,197 | 1,701,529.83 | 0.1832 |